ММВБ 3 913 -0,9%  Nasdaq 15 085 -1,9%  Биткойн 49 145 -0,5%  USD/RUB 73,7180 0,0% 
РТС 1 668 -1,3%  S&P500 4 538 -0,8%  Нефть 71,3 1,6%  EUR/RUB 83,2530 -0,5% 
Dow 34 580 -0,2%  FTSE100 7 122 -0,1%  Золото 1 783 0,0%  EUR/USD 1,1293 -0,1% 

Targovax ASA - Профиль

Targovax ASA is a clinical stage holding company. The firm focuses on the development and commercialization of immuno-oncology. Its product includes ONCOS-102, genetically modified oncolytic adenovirus, which is used to infect cancer cells and activate the immune system to fight the cancer. The company was founded on October 1, 2010 and is headquartered in Lysaker, Norway.

Акционеры

Название Доля (%)
Freefloat99,89
HealthCap AB14,33
Radiumhospitalets Forskningsstiftelse5,11
Fjärde AP-fonden4,62
Fjarde AP Fonden3,94
Martin Aage Thorendahl2,02
Nordea Kapital2,02
Per Wold1,98
Nordea Avkastning1,90
KLP Kapitalforvaltning AS1,63
Cicero World 0-1001,47
Egil Pettersen1,46
Nordea Norge Pluss1,24
MP Pensjon PK1,15
Sundt Family1,11

Адрес

а/я:
Телефон:
Факс:
Вэб:

Менеджмент

Добавить или редактировать инструмент